Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Conditions: Female Breast Cancer Patients; Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer; HRD Positive Advanced Breast Cancer Interventions: Drug: Adebrelimab plus Fluzoparib Sponsors: Zhejiang Cancer Hospital; Jiangsu Hengrui Pharmaceutical Co., Ltd. Not yet recruiting

https://clinicaltrials.gov/study/NCT06254066

Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials